EMA's CHMP wants more Avandia information

The European Medicines Agency's CHMP submitted further questions to GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) after meeting on Wednesday to discuss the safety of the pharma's diabetes drug Avandia rosiglitazone. The agency plans to disclose the questions at its regular monthly meeting, scheduled for Sept. 20-23, during which it expects to finalize the review of Avandia. GSK declined to comment. ...